MSMuraz A. Shambatov

Muraz A. Shambatov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muraz A. Shambatov has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevention of venous thromboembolic events in orthopedic patients: the role of Doppler ultrasound

    by A. V. Chubatov, M. A. Shambatov, N. V. Izmozherova, S. V. Chubatova, P. A. Lebedeva, А. В. Чубатов, М. А. Шамбатов, Н. В. Изможерова, С. В. Чубатова, П. А. Лебедева

    Aim.  To evaluate the effectiveness of screening ultrasound of lower limb veins as an additional measure for the prevention of venous thromboembolic (VTE) events in the early postoperative period in patients undergoing elective orthopedic surgery on large joints. Particular attention is paid to identifying preclinical thrombosis and subsequently adapting anticoagulant therapy, including switching the patient to therapeutic doses of direct oral anticoagulants. Material and methods.  This study included a retrospective review of the medical records of 4359 patients who underwent elective surgery between September 2020 and July 2022 at the Tetyukhin Ural Clinical Treatment and Rehabilitation Center. All patients underwent a focal ultrasound of the lower limb deep vein system using the Sonosite MicroMaxx™ system in B-mode with color Doppler mapping within the first 24 hours after surgery. All patients received standardized prophylactic therapy with rivaroxaban at a dose of 10 mg or 15-20 mg (as indicated) once daily. If deep vein thrombosis was detected, further therapy was in accordance with current clinical guidelines. Results. The study included 4359 patients who underwent orthopedic surgery: 3071 women (70%) and 1288 men (30%). Lower limb deep vein thrombosis (DVT) was diagnosed in 345 patients (7,9%). The highest proportion of patients were elderly (60-74 years, 46,8%), followed by middle-aged (45-59 years, 33,8%) and young (18-44 years, 12,6%) patients. The incidence of DVT differed by sex and age as follows: in women of younger age groups (Conclusion. In this study, the use of routine ultrasound screening enabled non-invasive and highly accurate detection of both proximal and distal thromboses. Early ultrasound screening detects thromboses at a preclinical stage, enables timely adjustment of anticoagulant therapy, and reduces the risk of complications. Prospective studies are needed to confirm long-term effectiveness.

  • The role of the genetic factor in the development of sarcopenia

    by K. S. Ispavskaya, N. V. Izmozherova, A. A. Popov, I. A. Pashkina, E. V. Kudryavtseva, D. L. Zornikov, M. A. Shambatov, V. S. Ermakov, V. N. Kravchuk, V. V. Dalinin

    Objectives. To assess the associative relationship between genotype distributions of polymorphic variants of COL1A1, VDR, NOS3, IL6, RANKL, MTHFR, MTR, MTRR genes and risk of sarcopenia in women over 60 years of age. Materials and methods. This cross-sectional study enrolled 67 women aged 61 to 82 years. Dynamometry and a “Chair rising test” test have been performed. Polymorphic variants of the COL1A1, VDR, NOS3, IL6, RANKL, MTHFR, MTR, MTRR genes have been identified. The participants were divided into 2 groups: group 1 consisted of 34 subjects without sarcopenia and group 2 included 33 persons with sarcopenia. Results . In group 1, the GG G894T NOS3 genotype significantly prevailed, and in group 2, the GT and TT variants were most frequent, p = 0.035. In group 1, the recessive TT genotypes G894T NOS3, GG A66G MTRR prevailed. CC variant G(-174)IL6 prevailed in group 2, as did the TT C677T MTHFR genotype, which was not detected in group 2, p < 0.05. Conclusions. Age is an independent risk factor for sarcopenia development. Presence of the TT G894T NOS3, GG A66G MTRR genotype is likely to increase the risk of sarcopenia. While the CC G174C IL6, TT C677T MTHFR genotype is probably protective against the development of sarcopenia. There was no association between the genotype distributions of polymorphic variants of the COL1A1, VDR, RANKL, MTR genes and the risk of sarcopenia in women over 60 years of age.

  • Open Access

    Real-world data on managing patients with coronary artery disease and multifocal atherosclerosis. Results of the 12-month international clinical registry of patients with identified multifocal atherosclerosis in the Russian Federation and Eurasian countries (KAMMA)

    by G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, T. I. Batluk, N. A. Koziolova, A. I. Chesnikova, А. Ю. Васькин, D. S. Tokmin, I. G. Bakulin, O. L. Barbarash, et al.

    Aim. To study real-world data on managing patients with coronary artery disease (CAD) and multifocal atherosclerosis (MFA) for 12 months by outpatient cardiologists.Material and methods. KAMMA is a real-world registry organized by the Eurasian Association of Therapists. The main branch included men and women over 18 years of age with confirmed atherosclerosis in two or more arterial systems and one or more risk factors for atherosclerosis. The start date for patient recruitment was February 1, 2022 and the end date was November 27, 2022. The design included 3 following visits: 1 — baseline, 2 — after 6 months, 3 — after 12 months. Twentyeight research centers were located in 7 federal districts of the Russian Federation, as well as in the Republics of Kazakhstan, Uzbekistan and Belarus.Results. A patient population (n=2905) was formed, all of whom had verified CAD. The mean age was 66,0 [59,0; 72,0] years (men — 60,3%). Low-density lipoprotein cholesterol decreased by 20,4% over 12 months, while non-high-density lipoprotein cholesterol — by 12,7%. Over 12 months, lipid-lowering therapy did not undergo significant changes. Statin monotherapy was maintained in 83%, of which only 53,7% of patients received high-dose therapy. Combined statin+ezetimibe therapy was used in 12,4%, while statin+ezetimibe+PCSK9 inhibitor — in 4,6%. During the 1-year follow-up, antithrombotic therapy was not enhanced. Low prescription rate of combination therapy with antiplatelet agents (15,7%) and low-dose rivaroxaban and acetylsalicylic acid (7,9%) remained. By the follow-up end, a high incidence of major adverse cardiovascular events (8,8%) was registered in patients included in the KAMMA registry.Conclusion. Despite the fact that patients with MFA have a very high cardiovascular risk, routine management of these patients is characterized by high clinical inertia. During the 1-year follow-up, lipid-lowering and antithrombotic therapy was not properly strengthened, due to which the target levels of key lipid profile parameters were not achieved and a high rate of major adverse cardiovascular events was observed in patients included in the registry.


  • Open Access

    Role of renin-angiotensin-aldosterone system gene polymorphisms in the development of diastolic dysfunction in female patients with hypertension

    by Mariya A. Grenaderova, Nadezhda V. Izmozherova, Elena V. Kudryavtseva, Muraz A. Shambatov, Danila L. Zornikov, Artem A. Popov, Anna A Vikhareva, Daniil O. Kornilov, Mikhail A. Tryapitsyn, Veronika M. Simarzina, et al.

    BACKGROUND: Cardiovascular diseases, including hypertension, cause approximately 17 million deaths annually, with 9.4 million directly attributable to hypertension, which affects nearly 40% of the adult population. Genetic polymorphisms in the renin-angiotensin-aldosterone system play a significant role in the development of hypertension and in response to therapy. Investigating candidate gene polymorphisms involved in renin-angiotensin-aldosterone system pathways may help optimize the selection of antihypertensive therapy at early stages of treatment. AIM: To assess the frequency of single-nucleotide polymorphisms in renin-angiotensin-aldosterone system genes and their contribution to the development of diastolic dysfunction. MATERIALS AND METHODS: A cross-sectional study was conducted in 87 postmenopausal women aged 67 years (interquartile range, 65–70 years). Single-nucleotide polymorphisms in the ADD1, AGT, AGTR1, AGTR2, CYP11B2, GNB3, NOS3 genes were analyzed using real-time polymerase chain reaction. Renin-angiotensin-aldosterone system-related gene polymorphisms were evaluated in patients with and without diastolic dysfunction, as assessed by transthoracic echocardiography. RESULTS: No significant differences in the main clinical characteristics or the structure of antihypertensive therapy were observed between the groups with and without diastolic dysfunction (p 0.05). The current study did not reveal statistically significant differences in the distribution of polymorphic genotypes (p 0.05) The T allele of the CYP11B2 344 C/T polymorphism was significantly more frequent in patients with diastolic dysfunction. A two-locus model including AGT and CYP11B2 gene polymorphisms demonstrated a sensitivity of 66.1% and a specificity of 67.7%. The most effective three-locus model included polymorphisms in AGTR2, CYP11B2, and NOS3, yielding a sensitivity of 80.4% and a specificity of 71.0%. CONCLUSION: Multilocus analysis and a predictive model based on a combination of gene polymorphisms may support the assessment of risk for developing diastolic dysfunction in patients with hypertension. Identifying the contribution of genetic factors to the development of cardiovascular diseases and understanding their clinical relevance may facilitate the personalization of therapy.


  • Open Access

    Analysis of Pharmacotherapy of Arterial Hypertension in Multimorbid Patients

    by N. V. Izmozherova, A. A. Popov, A. A. Kuryndina, E. I. Gavrilova, M. A. Shambatov, V. M. Bakhtin

    Introduction. Arterial hypertension (AH) is the most common chronic non-communicable disease, especially among individuals over 60 years old, where its prevalence exceeds 60%. The relationship between blood pressure (BP) levels and the risk of cardiovascular events is observed across all age groups. The aim of the study was to assess the adequacy of antihypertensive therapy in outpatient multimorbid patients of different age groups.Materials and methods. The study included 323 outpatient patients with verified AH (92 men and 231 women). Patients were divided into three age groups: middle-aged, elderly, and old age. The frequency of achieving target BP levels, the structure of antihypertensive therapy, and the prescription of lipid-lowering and antiplatelet agents were evaluated.Results. The severity of AH did not differ between the groups. In the elderly groups, patients with high cardiovascular risk and comorbidities such as type 2 diabetes and osteoarthritis predominated. The most frequently prescribed medications were inhibitors of the renin-angiotensin-aldosterone system (94.1%). Target BP levels were mainly achieved due to systolic pressure (60%), while diastolic pressure was only controlled in 22% of cases.Discussion. The results are consistent with previous studies.Conclusion. AH in elderly patients is associated with high comorbidity and cardiovascular risk. Achieving target BP levels is possible with combination therapy, including renin-angiotensin-aldosterone system blockers and calcium antagonists. Additional treatment strategies are needed to reduce the residual risk of cardiovascular diseases.


  • Open Access

    Pharmacogenetics of warfarin: A literature review

    by Nadezhda V. Izmozherova, Muraz A. Shambatov, Artem A. Popov, Daria E. Zhuk, Viktoria A. Solodchenko

    Warfarin is an oral indirect anticoagulant that is widely used for the prevention of thromboembolic events. Pharmacogenetic testing is the most promising approach to personalizing warfarin treatment. In this review, we aimed to summarize how the patients’ genetic predispositions affect the pharmacokinetics of warfarin, which determines the different dosing regimens for patients. To correctly interpret data in clinical settings, algorithms for selecting the optimal dosing regimen need to be developed that consider the patient’s age, sex, weight, height, health status, and genetic characteristics. These algorithms could help determine the optimal dose, enhance patient adherence to treatment, and increase the physician’s confidence in the treatment safety. Furthermore, although algorithms that consider SNPs in the CYP2C9, VKORC1, and CYP4F2 genes are more effective in predicting warfarin doses, their effectiveness varies according to race.


  • Open Access

    Patients With Non-Obstructive Coronary Artery Disease and Polyvascular Disease. Sub-Analysis of the Real-World Registry KAMMA (Clinical Registry on Patient Population With Polyvascular Disease in the Russian Federation and Eurasian Countries)

    by G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, T. I. Batluk, N. A. Koziolova, A. I. Chesnikova, A. Yu. Vaskin, D. S. Tokmin, I. G. Bakulin, O. L. Barbarash, et al.

    Aim. To study the clinical status and data of laboratory and instrumental examination of patients with non-obstructive ischemic heart disease (IHD) and multifocal atherosclerosis (MFA) included in the KAMMA registry. Material and methods. The subanalysis included 1,893 IHD patients who underwent coronary angiography (CAG) and ultrasonic examination of peripheral arteries. Based on the CAG data, patients were divided into two groups: group 1, patients with obstructive coronary atherosclerosis (CA) (maximum stenosis ≥50% and/or history of percutaneous coronary intervention/coronary artery bypass grafting, n=1728; 91.3%) and group 2, patients with non-obstructive CA (maximum stenosis Results. A comparative analysis based on the degree of coronary obstruction in patients with verified IHD who were included in the KAMMA registry showed that 8.7% of them had coronary artery stenosis of less than 50%. The overwhelming majority of patients with non-obstructive CA had MFA affecting the brachiocephalic arteries in 94.3% and the lower extremity arteries in 40.2%. Among patients with non-obstructive IHD, women predominated; risk factors such as smoking and type 2 diabetes mellitus were less frequent in this group than in the obstructive IHD group. Patients with non-obstructive CA more frequently had a history of dyslipidemia; they had higher total cholesterol and non-high-density lipoprotein cholesterol; and they more frequently received moderate-intensity statin therapy than patients with obstructive CA (55.8% vs. 34.5%). Characteristic features of patients with non-obstructive CA were less severe IHD and less frequent history of acute coronary syndrome. However, the incidence of stroke, peripheral arterial thrombosis, and chronic arterial insufficiency of the lower extremities did not differ in groups 1 and 2, whereas the incidence of paroxysmal atrial fibrillation was higher in the non-obstructive IHD group. Conclusion. IHD patients without coronary obstruction also require assessment of the peripheral arterial status, as they may have advanced MFA, which should be taken into account when choosing the “aggressiveness” of therapy.


  • Open Access

    Peculiarities of polyvascular disease and the diagnostic significance of the ankle-brachial index in patients with coronary artery disease: results from the real-world registry KAMMA (Clinical registry on patient population with polyvascular disease in the Russian Federation and Eurasian countries)

    by G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, T. I. Batluk, N. A. Koziolova, A. I. Chesnikova, А. Ю. Васькин, D. S. Tokmin, I. G. Bakulin, O. L. Barbarash, et al.

    Aim. To investigate the prevalence and characteristics of polyvascular disease in the Eurasian region's population with one or more previously established locations of atherosclerotic arterial damage, and to evaluate the diagnostic importance of the ankle-brachial index (ABI) as a marker for polyvascular disease (PVD).Material and methods. A total of 1837 patients were included in the main branch of the KAMMA registry (patients with PVD), among which 91,6% had coronary artery disease (CAD) (n=1683). For further analysis, the group of patients with CAD was combined with 1222 patients included in the second branch of the registry — KAMMA-cardio, forming a patient population (n=2905), in which all patients had verified CAD. The mean age of patients was 66,0 [59,0; 72,0] years, with 60,3% being male. Peripheral arteries was assessed using ultrasound examination.Results. PVD was present in 95,6% of patients with coronary atherosclerosis: dual-region involvement was observed in 51,3% of patients, three-region involvement in 37,1%, four-region involvement in 3,4%, and five-region involvement in 2,0%. Stenoses of the common carotid artery were observed in 71% of patients, internal carotid artery — in 68%, lower limb artery — in 52%, and renal and mesenteric artery — in 8,3%. There were following diagnostic effectiveness of the ABI for detecting patients with lower limb artery stenosis was: sensitivity — 58,0%, specificity — 83,6%. The quality of antithrombotic and lipid-lowering therapy was insufficient.Conclusion. In the overwhelming majority (95,6%) of patients with CAD in the KAMMA registry, PVD was revealed, with nearly half of the patients having involvement in three or more arterial zones. In the patient population with CAD, there should be an active effort to identify patients with PVD, using at least the ABI determination and active modern antithrombotic and lipid-lowering therapy according to current clinical guidelines.


  • Open Access

    Markers of Collagen Degradation in Remodeling and Diastolic Dysfunction of Left Ventricle in Patients with Arterial Hypertension

    by M. A. Shambatov, N. V. Izmozherova, A. A. Popov, I. F. Grishina, E. V. Kudryavtseva, V. V. Bazarnyi, L. G. Polushina, M. A. Kopenkin

    Introduction. Myocardial remodeling is a consequence or predictor of several cardiovascular diseases. The key process in myocardial remodeling is the degradation of collagen fibers, mediated by the activity of matrix metalloproteinases and their tissue inhibitor.The aim of this study was to evaluate serum levels of matrix metalloproteinase type 9 and tissue inhibitor of matrix metalloproteinase type 1 in female patients with arterial hypertension, myocardial remodeling, and diastolic dysfunction.Materials and methods. A cross-sectional study that included 84 postmenopausal women. All patients underwent echocardiography. Left ventricular remodeling was assessed according to Ganau classification, and diastolic function was evaluated using transmittal flow parameters. Serum analysis included the determination of MMP-9 and TIMP-1 levels using an enzyme-linked immunosorbent assay.Results. The median concentration of MMP-9 in the sample was 2 295.00 (923.60–4 114.00) ng/ml, TIMP — 1–17 010.00 (16 780.00–17 170.00) ng/ml. When evaluating the echocardiographic parameters of the patients included in the study, changes were revealed that indicate structural and functional remodeling of the LV and DD. 29 patients (35 %) had normal geometry, 6 patients (7 %) had concentric myocardial remodeling, 21 patients (25 %) had concentric myocardial hypertrophy, 28 cases (33 %) had eccentric myocardial hypertrophy. Statistically significant changes in the activity of MMP-9 and TIMP-1 were revealed in patients with various structural and geometric variants of remodeling. DD was detected in all patients included in the study: I degree was detected in 25 patients (30 %), II degree was determined in 59 cases (70 %). Using one-way analysis of variance, statistically significant differences in the level of MMP-9 in patients with grades I and II DD were determined. MMP-9 and MMP-9/TIMP-1 in patients with grade II DD are significantly higher than in patients with grade I.Discussion. Under pathophysiological conditions, the proteolytic properties of MMP-9 contribute to the stimulation of the immune response, initiating pathogenesis and aggravating the progression of the disease. Evaluation of the activity of MMP-9 and TIMP-1 in patients with arterial hypertension may be a marker of myocardial remodeling.Conclusion. An increase in the activity of matrix metalloproteinase type 9 and a decrease in the activity of a tissue inhibitor of matrix metalloproteinases type 1 were revealed in patients with arterial hypertension, myocardial remodeling and LV diastolic dysfunction. The level of MMP-9 is associated with the degree of diastolic dysfunction and the structural-geometric type of LV remodeling.


  • Open Access

    Morphometric variants of remodeling and diastolic function of the left ventricle in late postmenopausal patients with vitamin D deficiency

    by M. A. Shambatov, N. V. Izmozherova, A. A. Popov, I. F. Grishina, A. A. Vikhareva, A. V. Ryabinina

    Aim. To reveal the features of the structural-geometric remodeling of the left chambers of the heart, the diastolic function of the left ventricle and to assess the presence of calcification of the valvular structures of the heart in late postmenopausal women with different levels of vitamin D. Material and methods. The cross-sectional study included 123 postmenopausal women. A standard transthoracic echocardiography was performed with an assessment of morphometric variants of remodeling of the left chambers of the heart and its diastolic function according to the transmitral flow. The significance of differences was assessed using the Mann–Whitney test, χ2 Pearson. Differences and correlations were considered significant at p < 0.05. Results. The median concentration of 25(OH)D in the sample was 20.51 ng/ml (15.8÷26.73). Adequate serum concentration of 25(OH)D was observed in 23 (19%) patients (group 1), in 100 (81%) cases vitamin D deficiency was detected (group 2). In group 1 — 7 (31%) patients had normal geometry (NG) of the left ventricle (LV), LV concentric remodeling (CR) was diagnosed in 1 (4%) case, LV concentric hypertrophy (CH) was diagnosed in 3 (13%) cases, and LV eccentric hypertrophy (EH) was detected in 12 (52%) cases. In Group 2, LV NG was diagnosed in 27 (27%) cases, LV CR was detected in 8 (8%) cases, LV CH was detected in 31 (31%) cases, and LV EH was verified in 34 (34%) cases, the differences are insignificant (p = 0.24). Patients of group 2 showed a statistically significant increase in the volume of the right atrium (RA) and thickness of the posterior wall of the left ventricle (TZSLV). In group 1, in 11 (50%) cases, rigid-type diastolic dysfunction (DD) was detected, and in 11 (50%) cases, a pseudo-normal type of DD was detected. In group 2, pseudonormal myocardial DD was detected in 26 (26%) patients, 74 (74%) patients had rigid-type DD, differences between groups were significant (p < 0.001). Calcifications were found in the annulus fibrosus in 16 (70%) cases in group 1 and in 88 (88%) patients in group 2, the differences were significant (p = 0.04). Conclusion. In the study, data were obtained indicating a significant contribution of vitamin D deficiency to changes in the geometry of the left chambers of the heart, diastolic function of the left ventricle, and calcification of valvular structures.